"This is an exciting time in neuroscience and rare disease drug development and we remain on track for the readout of the placebo-controlled ANAVEX 2-73 Phase 2b/3 Alzheimer’s disease clinical trial, a condition of significant unmet need and economic burden for which there are only limited approved pharmacological treatment options," said Christopher U Missling, PhD, President and CEO of Anavex. "Our recent progress highlights the potential of our clinical Precision Medicine SIGMAR1 platform and portfolio, and we look forward to sharing additional program and data updates."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AVXL:
- Anavex Shares (NASDAQ: AVXL) Plunge after Q4 Earnings Miss
- Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
- Anavex management to meet with Piper Sandler
- Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
